You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 403 Early results from a phase 1 study to evaluate safety, pharmacokinetics, and efficacy of AMG 404, a programmed death-1 (PD-1) antibody, in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
403 Early results from a phase 1 study to evaluate safety, pharmacokinetics, and efficacy of AMG 404, a programmed death-1 (PD-1) antibody, in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020135019
Dec 202046016
Jan 20214206
Feb 20213808
Mar 2021130015
Apr 202176012
May 20213409
Jun 20210017
Jul 2021008
Aug 20210014
Sep 20210016
Oct 2021120023
Nov 202197016
Dec 20215405
Jan 20223203
Feb 20226804
Mar 20228605
Apr 20224406
May 20226204
Jun 20225004
Jul 20222602
Aug 20224206
Sep 20223403
Oct 20226203
Nov 20224201
Dec 20226406
Jan 20233202
Feb 20235406
Mar 20232802
Apr 20232008
May 20234404
Jun 20232205
Jul 202326010
Aug 20233807
Sep 20231802
Oct 20234207
Nov 20236603
Dec 20237502
Jan 20243001
Feb 20244801
Mar 20244803
Apr 20243403
May 20242803
Jun 20243604
Jul 20244502
Aug 20244205
Sep 20244201
Oct 20243203
Nov 20244004
Dec 20244404
Jan 20254006
Feb 20251403
Mar 2025009
Apr 2025006
May 2025004
Jun 2025004
Total23720355